V. Moebus

Andreas Schneeweiss, Nadia Harbeck, Christoph Thomssen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)

S. Loibl, V. Nekljudova, G. Minckwitz, 2011, Supportive Care in Cancer.

Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial

R. Greil, J. Bergh, P. Malmström, 2019, Cancer.

Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients.

F. Marmé, S. Loibl, V. Nekljudova, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

C. Denkert, F. Marmé, S. Loibl, 2021 .

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

R. Kimmig, J. Blohmer, A. du Bois, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Interim results of Intergroup EC-Doc Trial: A randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC- docetaxel in patients with 1–3 positive lymph nodes

N. Harbeck, J. Huober, W. Kuhn, 2008 .

Investigation of the efficacy of imidazolyl ethanamide pentandioic acid (IEPA) to reduce chemotherapy-induced myelosuppression (CIM) in breast cancer patients.

P. Fasching, Marcus Schmidt, C. Jackisch, 2019, Journal of Clinical Oncology.

Abstract S3-04: The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer

S. Loibl, M. Untch, V. Nekljudova, 2015 .

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.

M. Aapro, M. Untch, U. Nitz, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2009, Breast Care.

Abstract P6-17-08: Brain metastases in breast cancer network Germany (BMBC, GBG 79): First analysis of 548 patients from the multicenter registry

T. Fehm, T. Kühn, T. Park-Simon, 2016 .

Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.

R. Greil, J. Bergh, P. Malmström, 2019, Journal of Clinical Oncology.

Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial)

T. Bauknecht, S. Costa, W. Meier, 2001 .

TOPOTECAN VERSUS TREOSULFAN IN EARLY RECURRENT OVARIAN CANCER AFTER PRIMARY PLATINUM/ PACLITAXEL CHEMOTHERAPY. A PROSPECTIVE RANDOMIZED PHASE III TRIAL OF THE AGO OVARIAN CANCER STUDY GROUP

A. Reuss, R. Kimmig, W. Kuhn, 2004, International Journal of Gynecologic Cancer.

Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)

R. Nanda, J. Cortes, L. Fehrenbacher, 2019, Poster Session Abstracts.